Tucson, Arizona 85704

  • Related Macular Degeneration


The purpose of the trial is to compare whether Macugen (pegaptanib sodium) in combination with PDT with Visudyne (verteporfin) is safe and effective in slowing down the leakage of fluid within the eye and thereby stabilizing or improving vision when compared to Macugen alone. Patients must be recently diagnosed with predominantly classic wet AMD and must be eligible for PDT.


Inclusion Criteria: - Subjects of either gender; aged 50 years or greater. - Subfoveal choroidal neovascularization (CNV) due to AMD with predominantly classic lesion composition - Best corrected visual acuity in the study eye between 20/40 and 20/200 Exclusion Criteria: - Any prior PDT with Visudyne to the study eye - Any previous AMD thermal laser therapy to the study eye



Primary Contact:


Backup Contact:


Location Contact:

Tucson, Arizona 85704
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.